A Phase 2 interventional study of Placebo and Brivaracetam in Epilepsy, sponsored by UCB Pharma. Completed at 42 sites in 4 countries. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-10-02.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.
Among the 34 studies testing brivaracetam in Epilepsy, this one is the 10th largest by enrollment, is one of 4 that started in 2005, is one of 6 in phase 2, and was the 2nd registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Belgium, Czechia and 8 more countries
Ages 1 mo+
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 16 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2005.
This study's enrollment of 210 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 34 interventional studies. Of the 31 that completed or were terminated, 23 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 44th largest by enrollment of the 116 interventional ones that give a count, is one of 8 that started in 2005, is one of 26 in phase 2, and was the 14th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing brivaracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Matching Placebo tablets administered twice a day
Other: Placebo
Brivaracetam 5 mg/day, 2.5 mg administered twice a day
Drug: Brivaracetam
Brivaracetam 20 mg/day, 10 mg administered twice a day
Drug: Brivaracetam
Brivaracetam 50 mg/day, 25 mg administered twice a day
Drug: Brivaracetam
Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 7-week Treatment Period
Daily oral dose of two equal intakes, morning and evening, of Brivaracetam over the 7-week Treatment Period
Also known as: Briviact
Partial Onset Seizure Frequency Per Week During the 7-week Treatment Period
Calculated as 7-day partial onset seizure frequency.
Time frame: During the 7-week Treatment Period
Percentage Change From Baseline in Partial Onset Seizure Frequency Per Week (Type I) Over the 7-week Treatment Period
Calculated as 7-day seizure frequency during the 7-week Treatment Period - 7-day seizure frequency during the Baseline Period, divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in partial seizure frequency from Baseline.
Time frame: Baseline, during the 7-week Treatment Period
Seizure Frequency Per Week for All Seizures (Types I +II +III) Over the Treatment Period
Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or nonconvulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 7-day period.
Time frame: During the 7-week Treatment Period
Absolute Change From Baseline in Seizure Frequency Per Week for Partial Onset Seizures (Type I) Over the Treatment Period
Calculated as 7-day Partial Onset Seizures (Type I) frequency during the 7-week Treatment Period 7-day seizure frequency during the Baseline Period. A negative value from Baseline indicates a decrease in partial seizure frequency from Baseline.
Time frame: During the 7-week Treatment Period
Absolute Change From Baseline in Seizure Frequency Per Week for All Seizures (Types I + II + III) Over the Treatment Period
Calculated as 7-day seizure frequency during the 7-week Treatment Period 7-day seizure (Types I + II + III) frequency during the Baseline Period. A negative value from Baseline indicates a decrease in partial seizure frequency from Baseline.
Time frame: During the 7-week Treatment Period
Percentage Change From Baseline in Seizure Frequency Per Week for All Seizures (Types I + II + III) Over the Treatment Period
Calculated as 7-day seizure frequency during the 7-week Treatment Period - 7-day seizure frequency during the Baseline Period, divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in partial seizure frequency from Baseline.
Time frame: During the 7-week Treatment Period
Responder Rate in Partial Onset Seizures (Type I) Over the Treatment Period
A responder was defined as a subject with a \>= 50 % reduction in seizure frequency per week from the Baseline Period to the end of the Treatment Period.
Time frame: During the 7-week Treatment Period
Percentage of Subjects With Categorized Response to the Treatment in Partial Onset Seizures (Type I) Over the Treatment Period
Categories of percentage reductions in seizures from baseline were as following: \< -25 %; -25 % to \<25 %; 25 % to \<75 %; 75 % to \<100 %; 100 %.
Time frame: During the 7-week Treatment Period
Percentage of Subjects Who Are Seizure Free During the 7-week Treatment Period
A subject was considered seizure free, if no seizure was reported during the 7-week Treatment Period.
Time frame: During the 7-week Treatment Period
Number of Seizure-free Days Per 4 Weeks
A day was considered seizure-free, if no seizure was reported during 24 hours.
Time frame: Baseline, during the 7-week Treatment Period
Time to Nth (n= 1, 5, 10) Seizure During the 7-week Treatment Period
Number of days to first, fifth, and tenth seizure after baseline.
Time frame: During the 7-week Treatment Period
The study started to enroll patients in November 2005 and concluded in June 2006.
| Milestone | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day |
|---|---|---|---|---|
| Started | 54 | 50 | 52 | 52 |
| Completed | 49 | 46 | 51 | 51 |
| Not completed | 5 | 4 | 1 | 1 |
| Withdrew: Adverse event | 3 | 2 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
Calculated as 7-day seizure frequency during the 7-week Treatment Period - 7-day seizure frequency during the Baseline Period, divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in partial seizure frequency from Baseline.
| percentage of change | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day |
|---|---|---|---|---|
| Percentage Change From Baseline in Partial Onset Seizure Frequency Per Week (Type I) Over the 7-week Treatment Period | -21.7 (-42.99 to 12.04) | -29.91 (-53.33 to -3.83) | -42.56 (-67.92 to 0.44) | -53.04 (-69.33 to -19.56) |
Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or nonconvulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 7-day period.
| seizures per week | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day |
|---|---|---|---|---|
| Baseline | 2.23 (1.30 to 4.22) | 2.21 (1.38 to 5.00) | 2.50 (1.50 to 6.06) | 1.99 (1.36 to 3.97) |
| Treatment | 1.81 (0.88 to 3.50) | 1.61 (0.75 to 4.34) | 1.70 (0.59 to 3.97) | 0.92 (0.69 to 2.05) |
Calculated as 7-day Partial Onset Seizures (Type I) frequency during the 7-week Treatment Period 7-day seizure frequency during the Baseline Period. A negative value from Baseline indicates a decrease in partial seizure frequency from Baseline.
| seizures per week | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day |
|---|---|---|---|---|
| Absolute Change From Baseline in Seizure Frequency Per Week for Partial Onset Seizures (Type I) Over the Treatment Period | -0.37 (-1.18 to 0.19) | -0.66 (-1.19 to -0.07) | -0.84 (-2.21 to -0.08) | -0.92 (-2.44 to -0.24) |
Calculated as 7-day seizure frequency during the 7-week Treatment Period 7-day seizure (Types I + II + III) frequency during the Baseline Period. A negative value from Baseline indicates a decrease in partial seizure frequency from Baseline.
| seizures per week | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day |
|---|---|---|---|---|
| Absolute Change From Baseline in Seizure Frequency Per Week for All Seizures (Types I + II + III) Over the Treatment Period | -0.40 (-1.18 to 0.19) | -0.66 (-1.19 to -0.07) | -0.80 (-2.21 to -0.08) | -0.92 (-2.44 to -0.37) |
Calculated as 7-day seizure frequency during the 7-week Treatment Period - 7-day seizure frequency during the Baseline Period, divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in partial seizure frequency from Baseline.
| percentage of change | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day |
|---|---|---|---|---|
| Percentage Change From Baseline in Seizure Frequency Per Week for All Seizures (Types I + II + III) Over the Treatment Period | -24.35 (-43.61 to 12.00) | -29.91 (-53.33 to -3.83) | -41.57 (-65.31 to 0.44) | -53.05 (-69.33 to -22.82) |
A responder was defined as a subject with a \>= 50 % reduction in seizure frequency per week from the Baseline Period to the end of the Treatment Period.
| percentage of participants | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day |
|---|---|---|---|---|
| Responder Rate in Partial Onset Seizures (Type I) Over the Treatment Period | 16.7 | 32.0 | 44.2 | 55.8 |
Categories of percentage reductions in seizures from baseline were as following: \< -25 %; -25 % to \<25 %; 25 % to \<75 %; 75 % to \<100 %; 100 %.
| percentage of participants | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day |
|---|---|---|---|---|
| < -25% | 18.5 | 8.0 | 9.6 | 13.5 |
| -25% to <25% | 35.2 | 38.0 | 30.8 | 13.5 |
| 25% to <75% | 40.7 | 42.0 | 40.4 | 55.8 |
| 75% to <100% | 1.9 | 4.0 | 11.5 | 9.6 |
| 100% | 3.7 | 8.0 | 7.7 | 7.7 |
A subject was considered seizure free, if no seizure was reported during the 7-week Treatment Period.
| percentage of participants | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day |
|---|---|---|---|---|
| Completed the Period | 1.9 | 8.0 | 7.7 | 5.8 |
| Discontinued from the Period | 1.9 | 0 | 0 | 0 |
A day was considered seizure-free, if no seizure was reported during 24 hours.
| Days/4 Weeks | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day |
|---|---|---|---|---|
| Number of Seizure-free Days Per 4 Weeks | 22.66 (16.57 to 24.57) | 22.86 (15.43 to 25.14) | 22.84 (18.57 to 25.71) | 24.65 (21.14 to 25.86) |
Number of days to first, fifth, and tenth seizure after baseline.
| days | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day |
|---|---|---|---|---|
| Number of days to first seizure after baseline | 4.0 (3.0 to 6.0) | 4.0 (3.0 to 7.0) | 4.5 (2.0 to 8.0) | 7.0 (4.0 to 13.0) |
| Number of days to fifth seizure after baseline | 17.0 (13.0 to 22.0) | 20.0 (17.0 to 27.0) | 18.5 (14.0 to 29.0) | 32.5 (23.0 to 42.0) |
| Number of days to tenth seizure after baseline | 32.0 (23.0 to 45.0) | 38.0 (27.0 to NA) | 39.0 (23.0 to NA) | 57.0 (49.0 to NA) |
Calculated as 7-day partial onset seizure frequency.
| Seizures per week | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day |
|---|---|---|---|---|
| Partial Onset Seizure Frequency Per Week During the 7-week Treatment Period | 1.81 (0.88 to 3.50) | 1.61 (0.75 to 4.34) | 1.55 (0.57 to 3.83) | 0.92 (0.69 to 2.05) |
Collected over Adverse events were collected from Baseline until Safety Visit (up to 3 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/54 (0%) | 0/54 (0%) | 15/54 (27.8%) |
| Brivaracetam 5 mg/Day | 0/50 (0%) | 0/50 (0%) | 13/50 (26%) |
| Brivaracetam 20 mg/Day | 0/52 (0%) | 1/52 (1.9%) | 8/52 (15.4%) |
| Brivaracetam 50 mg/Day | 0/52 (0%) | 0/52 (0%) | 10/52 (19.2%) |
| Event | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day |
|---|---|---|---|---|
| NeurotoxicityNervous system disorders | 0/54 | 0/50 | 1/52 | 0/52 |
| Event | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 1/54 | 4/50 | 2/52 | 1/52 |
| InfluenzaInfections and infestations | 4/54 | 4/50 | 0/52 | 1/52 |
| HeadacheNervous system disorders | 4/54 | 4/50 | 2/52 | 1/52 |
| DizzinessNervous system disorders | 3/54 | 1/50 | 0/52 | 4/52 |
| SomnolenceNervous system disorders | 4/54 | 1/50 | 3/52 | 3/52 |
| FatigueGeneral disorders | 2/54 | 0/50 | 2/52 | 3/52 |
Baseline Characteristics refer to the Intention-to-Treat (ITT) Set.
| Age, Categorical(Participants) | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Total Title |
|---|---|---|---|---|---|
| <=18 years | 3 | 4 | 1 | 5 | 13 |
| Between 18 and 65 years | 51 | 46 | 50 | 47 | 194 |
| >=65 years | 0 | 0 | 1 | 0 | 1 |
| Age, Continuous(years) | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Total Title |
|---|---|---|---|---|---|
| Mean | 33.59 ± 11.26 | 32.72 ± 12.16 | 35.31 ± 13.66 | 30.92 ± 11.57 | 33.15 ± 12.20 |
| Sex: Female, Male(Participants) | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 20 mg/Day | Brivaracetam 50 mg/Day | Total Title |
|---|---|---|---|---|---|
| Female | 30 | 20 | 24 | 24 | 98 |
| Male | 24 | 30 | 28 | 28 | 110 |
Ran from Nov 2005 to primary completion in Jun 2006, 7 months.
Results were first posted in Aug 2018, 12 years 1 month after primary completion.
Of 45 industry-sponsored phase 2 interventional studies under Epilepsy, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 7 months is below that.
Counting every sponsor, half of 66 studies reached it within 23 months; a quarter within 14 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam